688185 康希诺
已收盘 01-06 15:00:01
资讯
新帖
简况
康希诺：2025年公司4款候选产品已获得批准IND/NDA
证券日报 · 01-06 21:32
康希诺：2025年公司4款候选产品已获得批准IND/NDA
康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准
证券日报 · 01-06 21:08
康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准
康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗
证券日报 · 01-06 21:07
康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗
康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症
证券日报 · 01-06 20:40
康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症
康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量
证券日报 · 01-06 19:40
康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量
康希诺生物获中国国家药监局批准开展PCV24相关临床试验
美股速递 · 01-05 16:56
康希诺生物获中国国家药监局批准开展PCV24相关临床试验
康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作
证券日报 · 2025-12-23
康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作
康希诺（688185）披露联合疫苗启动I期临床试验并完成首例受试者入组，12月19日股价下跌0.24%
证券之星 · 2025-12-19
康希诺（688185）披露联合疫苗启动I期临床试验并完成首例受试者入组，12月19日股价下跌0.24%
康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组
智通财经 · 2025-12-19
康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组
智通港股通资金流向统计(T+2)|12月8日
智通财经 · 2025-12-08
智通港股通资金流向统计(T+2)|12月8日
康希诺跌2.50% 2020年上市募52亿中信证券保荐
中金财经 · 2025-12-03
康希诺跌2.50% 2020年上市募52亿中信证券保荐
康希诺（688185）披露取消监事会及修订公司章程等议案获通过，11月27日股价下跌0.22%
证券之星 · 2025-11-27
康希诺（688185）披露取消监事会及修订公司章程等议案获通过，11月27日股价下跌0.22%
康希诺：关于回购A股股份注销实施的公告
证券日报 · 2025-11-26
康希诺：关于回购A股股份注销实施的公告
每周股票复盘：康希诺（688185）吸入用肺结核疫苗印尼启动I期临床
证券之星 · 2025-11-16
每周股票复盘：康希诺（688185）吸入用肺结核疫苗印尼启动I期临床
康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组
智通财经 · 2025-11-13
康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组
康希诺（688185）披露拟用公积金弥补亏损，11月11日股价下跌0.26%
证券之星 · 2025-11-11
康希诺（688185）披露拟用公积金弥补亏损，11月11日股价下跌0.26%
每周股票复盘：康希诺（688185）拟用公积金14.5亿元弥补亏损
证券之星 · 2025-11-09
每周股票复盘：康希诺（688185）拟用公积金14.5亿元弥补亏损
康希诺（688185）披露拟使用公积金弥补亏损，11月07日股价下跌0.26%
证券之星 · 2025-11-07
康希诺（688185）披露拟使用公积金弥补亏损，11月07日股价下跌0.26%
康希诺（688185）披露2025年A股限制性股票激励计划首次授予结果，10月27日股价上涨0.08%
证券之星 · 2025-10-27
康希诺（688185）披露2025年A股限制性股票激励计划首次授予结果，10月27日股价上涨0.08%
每周股票复盘：康希诺（688185）拟注销406098股并推股权激励
证券之星 · 2025-10-26
每周股票复盘：康希诺（688185）拟注销406098股并推股权激励
加载更多
公司概况
公司名称：
康希诺生物股份公司
所属行业：
医药制造业
上市日期：
2020-08-13
主营业务：
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是MCV4、PCV13i、MCV2、Ad5-nCoV、吸入用Ad5-nCoV及XBB.1.5变异株疫苗、Ad5-EBOV。
发行价格：
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":65.53,"timestamp":1767682801000,"preClose":64.79,"halted":0,"volume":1606099,"delay":0,"changeRate":0.0114,"floatShares":113999999,"shares":247000000,"eps":-0.575,"marketStatus":"已收盘","change":0.74,"latestTime":"01-06 15:00:01","open":65.68,"high":65.68,"low":64.66,"amount":105000000,"amplitude":0.0157,"askPrice":65.53,"askSize":7,"bidPrice":65.52,"bidSize":35,"shortable":0,"etf":0,"ttmEps":-0.575,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767749400000},"marketStatusCode":5,"adr":0,"adjPreClose":64.79,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767663000000,1767670200000],[1767675600000,1767682800000]],"highLimit":71.27,"lowLimit":58.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247043801,"isCdr":false,"pbRate":3.28,"roa":"--","roe":"0.29%","epsLYR":-1.53,"committee":0.010753,"marketValue":16189000000,"turnoverRate":0.014,"status":0,"afterMarket":{"amount":0,"volume":0,"close":65.53,"buyVolume":0,"sellVolume":0,"time":1767684837558,"indexStatus":"已收盘 01-06 15:30:00","preClose":64.79},"hkstockBrief":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":37.3,"timestamp":1767686895003,"preClose":36.38,"halted":0,"volume":1050000,"delay":0,"premium":"-48.98"},"floatMarketCap":7495000000},"requestUrl":"/m/hq/s/688185","defaultTab":"news","newsList":[{"id":"2601890033","title":"康希诺：2025年公司4款候选产品已获得批准IND/NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890033","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601890033?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:32","pubTimestamp":1767706320,"startTime":"0","endTime":"0","summary":"产品获批及研发端，2025年公司4款候选产品已获得批准IND/NDA，以及启动2个新的临床试验，以2026年设置的业绩考核目标A档来看，2026年至少包括5款候选产品获得批准IND、获得批准NDA，以及至少启动2个新的临床试验。目前也是在按既定的研发节奏推进，公司也会和药监、中检院及临床试验合作方等积极沟通，以期顺利推进相应候选产品的研发里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IND","688185","BK0239"],"gpt_icon":0},{"id":"2601897404","title":"康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897404","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601897404?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:08","pubTimestamp":1767704903,"startTime":"0","endTime":"0","summary":"证券日报网1月6日讯，康希诺在接受调研者提问时表示，公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准，并于同年12月启动I期临床试验，以评估其在2月龄~6岁人群中接种的安全性及免疫原性，与现有已上市及在研联苗产品形成差异化竞争。该联苗从临床需求的角度出发，考量了婴幼儿所需接种的疫苗品类，预期未来可提升婴幼儿群体接种的便利性和依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610446979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2601897400","title":"康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897400","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601897400?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:07","pubTimestamp":1767704853,"startTime":"0","endTime":"0","summary":"证券日报网1月6日讯，康希诺在接受调研者提问时表示，公司产品曼海欣?为目前国内唯一获批上市的四价流脑结合疫苗，是定位于中高端婴幼儿疫苗市场的产品，经过近几年的品牌建设、学术推广及市场教育，曼海欣?在国内的市场接受度以及渗透率逐步提升，其销售收入的稳步增长也证实了国内市场对于优质、高端的婴幼儿疫苗的需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610446761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185","159646"],"gpt_icon":0},{"id":"2601892483","title":"康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892483","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601892483?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:40","pubTimestamp":1767703205,"startTime":"0","endTime":"0","summary":"证券日报网讯1月6日，康希诺在互动平台回答投资者提问时表示，公司将在专注做好主营业务的基础上，利用搭建的mRNA技术平台在治疗领域持续探索更多适应症，如有阶段性进展，将会及时公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610427379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2601643891","title":"康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量","url":"https://stock-news.laohu8.com/highlight/detail?id=2601643891","media":"证券日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601643891?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:40","pubTimestamp":1767699626,"startTime":"0","endTime":"0","summary":"证券日报网讯1月6日，康希诺在互动平台回答投资者提问时表示，中检院自2021年4月中旬起不再公布疫苗产品的批签发数量，公司会参考同行的信息公示处理方式执行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610380937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","159646","BK0239"],"gpt_icon":0},{"id":"1147976460","title":"康希诺生物获中国国家药监局批准开展PCV24相关临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1147976460","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147976460?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:56","pubTimestamp":1767603417,"startTime":"0","endTime":"0","summary":"康希诺生物宣布，公司已正式获得中国国家药品监督管理局（NMPA）的临床试验批准，将启动针对PCV24（24价肺炎球菌结合疫苗）的相关临床研究。\n此次获批标志着康希诺在肺炎疫苗领域的研发取得重要进展，为后续产品上市奠定基础。PCV24疫苗若研发成功，有望为更广泛人群提供肺炎球菌感染的预防保护。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2593968413","title":"康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2593968413","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593968413?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:42","pubTimestamp":1766497324,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，康希诺在互动平台回答投资者提问时表示，公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作，持续与意向国家接触及探讨合作模式，并协同合作方开展临床试验及注册准入等相关工作，以加快公司产品的海外布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599763762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","688185","BK0239"],"gpt_icon":0},{"id":"2592985971","title":"康希诺（688185）披露联合疫苗启动I期临床试验并完成首例受试者入组，12月19日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592985971","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592985971?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:24","pubTimestamp":1766154282,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，康希诺报收于63.4元，较前一交易日下跌0.24%，最新总市值为156.63亿元。该股当日开盘63.36元，最高64.46元，最低63.36元，成交额达6440.61万元，换手率为0.88%。近日，康希诺生物股份公司发布公告称，其吸附无细胞百（组分）白破b型流感嗜血杆菌（结合）-ACYW135群脑膜炎球菌（结合）联合疫苗已启动I期临床试验，并完成首例受试者入组。公告提示，疫苗研发存在周期长、风险高等不确定性，敬请投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2592154407","title":"康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2592154407","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592154407?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:36","pubTimestamp":1766133419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺(688185.SH)发布公告，公司的吸附无细胞百(组分)白破b型流感嗜血杆菌(结合)-ACYW135群脑膜炎球菌(结合)联合疫苗(简称“DTcP-Hib-MCV4联合疫苗”)于近日正式启动I期临床试验，并完成首例受试者入组。I期临床试验为评价DTcP-Hib-MCV4联合疫苗在2月龄~6岁人群中接种的安全性及免疫原性的随机、部分盲法、剂量探索、阳性/安慰剂对照的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2589801348","title":"智通港股通资金流向统计(T+2)|12月8日","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801348","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801348?lang=zh_cn&edition=full","pubTime":"2025-12-08 07:31","pubTimestamp":1765150261,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月3日,小米集团-W、阿里巴巴-W、美团-W南向资金净流入金额位列市场前三，分别净流入8.71 亿、4.25 亿、2.99 亿腾讯控股、中芯国际、紫金矿业南向资金净流出金额位列市场前三，分别净流出-7.34 亿、-4.22 亿、-1.91 亿在净流入比方面，标智香港100、南方港美科技、新华文轩以100.00%、74.54%、72.97%位列市场前三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0054237671.USD","LU0348784397.USD","LU0683595622.HKD","HMTD.SI","LU1868837722.USD","LU2362541513.USD","SG9999002562.SGD","LU0326950275.SGD","LU0577902538.SGD","GB00BDT5M118.USD","LU0164865239.USD","LU1956131251.USD","IE0009570106.USD","LU2265009873.SGD","BK1615","LU0414403682.SGD","LU0516423174.USD","BK1592","LU0823039010.USD","LU1366334651.USD","LU2237443622.USD","LU1634259557.SGD","601899","LU2177674079.SGD","LU1868838027.USD","LU0918141705.HKD","LU0605514214.HKD","LU0266512473.USD","LU2087589342.USD","LU0289960550.SGD","LU1734074674.USD","BK1531","KSTmain","LU0588545730.USD","HK0000306701.USD","IE00BF5LJ272.USD","LU0320764755.SGD","LU0165289439.USD","LU1733274473.HKD","LU0210533765.USD","LU1883866441.USD","LU0648948544.HKD","LU0608807433.USD","LU0348723411.USD","LU0029874905.USD","BK1604","LU2449936058.SGD","SG9999014914.USD","LU2462611646.USD","LU1282649141.HKD","03143","06185","BK1184","IE00BZ08YR35.GBP","LU2097828557.USD","LU0862451753.SGD","IE00B0JY6N72.USD","BK1221","LU0823397285.USD","LU1634259391.SGD","LU1282651121.HKD","LU0608807946.USD","LU0651946864.USD","BK1589","LU0762540952.USD","LU2213484517.USD","HK0000252160.HKD","LU0543330483.HKD","IE0001KFT4U8.USD","SG9999018865.SGD","IE00BQJZWZ67.USD","LU0181495838.USD","LU0797268264.HKD","BK1116","LU0345780521.USD","LU0327786744.USD","LU0918141887.USD","IE00BZ08YS42.EUR","SG9999015952.SGD","LU0359201885.HKD","LU0164880469.USD","LU0149534421.HKD","LU0791590937.USD","LU0791591158.USD","LU0886674414.USD","SG9999001903.USD","LU0070217475.USD","LU0396098781.USD","LU1226288097.SGD","LU1242518857.USD","LU1807302812.USD","LU1794554557.SGD","LU0052750758.USD","LU1196710864.SGD","LU0828237510.HKD","LU1051769294.HKD","81810","688185","SGXZ86797644.SGD","LU0588545904.SGD","BK1618","SG9999014674.SGD","LU1102505929.USD","BK1560","BK1607","LU0640798160.USD","BK1109","LU0456846285.SGD","BK1584","LU1951186391.HKD","BK1501","LU2133065610.SGD","XIACY","IE0008368304.USD","IE00B0169N27.USD","LU0106259558.USD","LU0348788117.USD","LU1282651048.USD","LU0143863784.USD","LU2362540622.SGD","LU0348816934.USD","LU1323998911.USD","LU0130103400.USD","BK1583","LU0417516902.SGD","BK1224","LU0106252389.USD","IE00BVYPNP33.GBP","BK1568","LU0499858602.USD","BK1142","LU0326948709.USD","LU1880398471.USD","BK1575","LU0469268626.HKD","LU0359202008.SGD","BK1506","LU0455707207.USD","BK1528","LU0261947096.USD","BK1608","BK1574","LU0143863198.USD","LU1981816686.USD","LU0823426480.USD","SG9999014906.USD","SG9999015978.USD","IE00BGHQDM52.EUR","SGXZ81514606.USD","LU0502904849.HKD","LU1497734951.SGD","IE00B8HQ1Z84.USD","LU0128522744.USD","LU0264606111.USD","LU0047713382.USD","LU0163747925.USD","IE00BMPRXN33.USD","BK1550","BK1141","BK1591","LU2357305700.SGD","LU1504937902.USD","LU1733274390.USD","80883","BK1193","SG9999012710.SGD","SGXZ62798434.SGD","LU1226287792.SGD","LU0868486357.SGD","IE00B067MR52.USD","LU0048597586.USD","BK1515","LU0054450605.USD","LU0235996351.USD","LU1023057109.AUD","LU2237443465.HKD","LU1880383440.USD","LU1282649067.USD","BK1544","LU1224444064.USD","LU0594300179.USD","IE00B031HY20.USD","SG9999002950.SGD","BK1175","LU1439102457.SGD","BK1514","LU1655091459.SGD","LU1813983027.USD","LU0985320562.USD","BK1196","BK1614","LU0348805143.USD","SG9999015986.USD","LU2039709279.SGD","BK1095","LU1814569148.SGD","IE00BGV7N243.SGD","LU0251144936.SGD","LU1810669033.SGD","BK1570","LU0862451837.USD","LU0244354667.USD","LU0370786039.SGD","HK0000320223.HKD","LU0084288322.USD","LU0328353924.USD","LU0890818403.SGD","LU1960683339.HKD","600012","00811","LU0345769631.USD","LU1366334578.USD","LU2097828631.EUR","BK1133","LU0287142896.SGD","LU0823040885.USD","LU0117844026.USD","LU0173614495.USD","LU0831093199.SGD","LU1064130708.USD","LU2097829019.USD","IE00BMPRXR70.SGD","LU0633140560.USD","LU0449515922.USD","SG9999002828.SGD","BK1561","LU0231483743.USD","LU0197773160.USD","LU0878005551.USD","LU0417516571.SGD","02899","BK1235","LU1196710195.USD","LU0315179316.USD","BK1588","LU1188198961.HKD","SG9999012744.USD","LU0117841782.USD","SG9999001093.SGD","HTCD.SI","IE0032834883.USD","LU2488822045.USD","LU0128522157.USD","LU0449509016.USD","HK0000320264.USD","LU2097828714.EUR","BK1557","LU1196710351.USD","LU0630378429.USD","LU1961090484.USD","LU0203347892.USD","LU1993786604.SGD","BK1231","IE00BZ08YT58.USD","LU2498475776.HKD","LU0307460666.USD","LU0210526637.USD","LU0823038988.USD","SGXZ99366536.SGD","SG9999000418.SGD","81024","IE00B031HW06.USD","LU1917777945.USD","LU0164872284.USD","LU0348783662.USD","LU0348814723.USD","IE00B0169L03.USD","LU1282648689.USD","IE00BQXX3F31.USD","LU0499858438.USD","SG9999004220.SGD","LU0540923850.HKD","LU1235295612.USD","IE0003851619.USD","LU0577902454.USD","LU0456842615.SGD","LU0708995583.HKD","LU0348735423.USD","LU1102505762.USD","BK1617","LU0630378692.HKD","LU1044876610.USD","LU1242518931.SGD","LU2125910849.SGD","LU1785774172.SGD","LU2251237488.HKD","LU0880133367.SGD","LU0254981946.USD","LU0096374516.USD","LU0067412154.USD","SG9999006597.SGD","BK1152","LU3063872942.SGD","LU1115378108.SGD","LU0882747503.HKD","BK1587","89988","LU0477156797.USD","SG9999004311.SGD","LU0762541174.USD","SG9999000327.SGD","LU0737861699.HKD","LU0348825331.USD","02825","LU0501845795.SGD","LU0229945570.USD","LU0823397103.USD","LU1831875114.USD","LU0259732245.USD","LU0873338254.USD","LU0700851271.USD","IE0003795394.USD","LU0572940350.SGD","LU2237443549.SGD","LU1720051017.SGD","SG9999013353.USD","601811","LU1804176565.USD","LU0762542818.HKD","BK1566","688981","HBBD.SI","BK1207","IE00BQXX3D17.EUR","LU1224709979.USD","LU1251922891.USD","LU0345769128.USD","LU0672654166.SGD","BK1214","LU1725190679.HKD","LU1770034418.SGD","LU0516422440.USD","LU0345775950.USD","LU0819121731.USD","01810","LU0080751232.USD","LU0577902611.USD","IE00B543WZ88.USD","SG9999001689.USD","SG9999001051.SGD","LU0516422366.SGD","BK1238","LU2543165471.USD","LU0106959298.USD","LU0784639295.USD","LU1481107354.HKD","LU1497733631.SGD","BK1161","LU1770036033.HKD","LU0348766576.USD","LU0738912210.USD","LU1048588211.SGD","LU1719994722.HKD","LU0140636845.USD","LU0541501648.USD","LU0823413660.USD","LU0211977185.USD","LU1808992512.USD","LU1868837565.USD","LU0214875030.USD","HK0000165453.HKD","LU0127658192.USD","LU2051468812.USD","BK1555","IE00BWDBJ730.SGD","LU1316542783.SGD","SGXZ90724238.SGD","LU1211504680.USD","LU2008162690.USD","LU0737861772.HKD","SG9999000459.SGD","LU2125910500.SGD","LU0509642566.USD","LU0196878994.USD","LU0320764599.SGD","00995","LU1497733557.USD","LU2237443895.HKD","LU0011963245.USD","LU0577902298.EUR","SG9999014898.SGD","LU1226287529.USD","LU1880398554.USD","LU1439103000.SGD","LU0708995153.HKD","LU0828238088.HKD","BK1240","LU0871576103.HKD","LU1046422090.SGD","LU2293587155.HKD","LU0431992006.USD","LU2237443978.SGD","LU0865486749.SGD","SG9999018857.SGD","IE00BPRC5H50.USD","IE00BQXX3C00.GBP","SG9999002463.SGD","LU0211331839.USD","LU0228367735.SGD","LU0228659784.USD","LU0269904917.USD","LU0315178854.USD","LU1152091168.USD","SG9999012728.SGD","LU0531971595.HKD","LU0594300419.USD","LU0823413587.USD","LU0572944931.SGD","BK1567","LU1328277881.USD","HK0000252152.HKD","LU0348827113.USD","LU1064131003.USD","LU0048388663.USD","03442","BK1119","LU2242644610.SGD","BK1104","IE00B19Z5X02.USD","LU0169518387.USD","LU0197773673.USD","BK1130","LU1688375341.USD","LU0061477393.USD","BK1500","SG9999001226.SGD","LU0384037296.USD","LU2106854487.HKD","LU2279701549.SGD","LU0441854154.USD","IE0008368411.USD","LU0588546209.SGD","LU1769817096.USD","LU0456827905.SGD","LU1548497426.USD","LU2097828805.USD","LU2399975544.HKD","BK1163","LU1048596156.SGD","LU1718418525.SGD","LU2226246903.HKD","IE00B8L5B284.USD","LU1105468828.SGD","LU0634319403.HKD","BK1502","BK1594","LU0417516738.SGD","LU0463099449.HKD","LU1568876251.USD","BK1134","IE00BMCWC346.EUR","LU1629966141.USD","HXXD.SI","HK0000500386.USD","LU0314109678.HKD","LU0107464264.USD","LU0607220059.USD","LU0541502299.USD","LU0593848301.USD","BK1249","SG9999001846.SGD","IE0034224299.USD","LU0831103253.SGD","LU2778985437.USD","IE00B5MMRT66.SGD","SG9999006514.SGD","BK1586","LU0348767384.USD","LU0577902371.SGD","SG9999003461.SGD","LU2476274308.USD","HK0000306685.HKD","LU0572939691.SGD","LU1720050803.USD","LU1328615791.USD","LU0029875118.USD","LU0972618739.USD","LU1642822792.SGD","LU1044875133.USD","LU1201861165.SGD","LU0203345920.USD","SG9999017495.SGD","LU0261950983.USD","LU0345780281.USD","BK1523","LU1226288253.USD","LU0543330566.HKD","LU2097828474.EUR","00754","BK1233","LU0516423091.SGD","IE0031814852.USD","LU2148510915.USD","BK1505","LU0979878070.USD","LU2152927971.USD","LU0589944569.HKD","LU1880383366.USD","LU0819123356.HKD","LU0675040207.SGD","LU0648000940.SGD","SGXZ51526630.SGD","BK1526","LU2237443382.USD","IE0003895053.USD","LU2362541273.HKD","LU0175139822.USD","SG9999007991.SGD","LU0043850808.USD","LU2476274720.SGD","LU0266512127.USD","BK1191","BK1521","LU0348783233.USD","LU1303224171.USD","LU2247934214.USD","LU0823426308.USD","LU1568876335.HKD","LU0049853897.USD","LU0293314216.USD","LU0329678170.USD","BK1513","LU0345776255.USD","LU0210527791.USD","SG9999015945.SGD","BK1536","LU0650527681.SGD","LU0633140727.USD","LU0130518102.USD","LU1515016050.SGD","LU0856984785.SGD","LU1974910355.USD","LU0320764243.SGD","IE0008368742.USD","LU0149721374.USD","BK1236","LU0786609619.USD","IE0008369823.USD","LU0132412106.USD","LU0642271901.SGD","LU1044874839.SGD","LU1226288170.HKD","LU1152091754.HKD","IE00B3M56506.USD","BK1512","LU1282649810.SGD","BK1590","IE00BYV24P56.USD","BK1609","LU0049112450.USD","LU2023250504.SGD","ZIJMY","LU0878004406.USD","LU1769817179.HKD","LU2045819591.USD","IE0032431581.USD","LU0072462343.USD","SG9999012736.USD","LU2257852520.SGD","LU0488056044.USD","LU0828237940.HKD","SGXZ31699556.SGD","LU0051755006.USD","BK1227","IE00B031J352.USD","LU0359201612.USD","LU1226287875.USD","LU0531970944.HKD","SG9999014880.SGD","LU0898667661.SGD","LU0039217434.USD","LU0456854461.SGD","IE00B29SXG58.USD","LU0561508036.HKD","BK1517","BK1181","LU0048580855.USD","LU0588545490.SGD","LU1008478684.HKD","LU0651947912.USD","LU1720051108.HKD","BK1610","LU0329678337.USD","LU2317271919.USD","BK1225","LU2251237306.USD","IE00BVYPNQ40.USD","LU0611395673.USD","LU1522347837.USD","LU0188438112.USD","LU0192582467.USD","LU0072913022.USD","LU0516422952.EUR","LU1675838814.USD","IE00B97KM107.HKD","BK1198","BK1185","LU0823041008.USD","LU0821914370.USD","LU1048484197.HKD","SG9999001069.SGD","LU1051768304.USD","BK1516"],"gpt_icon":1},{"id":"2588014445","title":"康希诺跌2.50% 2020年上市募52亿中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014445","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014445?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:22","pubTimestamp":1764753726,"startTime":"0","endTime":"0","summary":"中国经济网北京12月3日讯 康希诺 今日股价下跌，截至收盘报65.63元，跌幅2.50%。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251203/31841808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1997245177.USD","LU1255011170.USD","LU1997245094.SGD","LU1997244956.HKD","BK0239","BK0276","688185","LU1064131003.USD","BK1147","LU2495084118.USD","LU0405327494.USD","LU1655091616.SGD","06030","LU1328615791.USD","BK0183","LU2289578879.USD","LU0405327148.USD","BK0196","LU1720050803.USD","600030","BK1516","BK0012","LU1064130708.USD","LU1794554557.SGD","BK0028","LU2148510915.USD","BK1521","BK0188","BK1564"],"gpt_icon":1},{"id":"2586225544","title":"康希诺（688185）披露取消监事会及修订公司章程等议案获通过，11月27日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586225544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586225544?lang=zh_cn&edition=full","pubTime":"2025-11-27 22:16","pubTimestamp":1764252987,"startTime":"0","endTime":"0","summary":"截至2025年11月27日收盘，康希诺报收于68.6元，较前一交易日下跌0.22%，最新总市值为169.47亿元。该股当日开盘68.6元，最高69.36元，最低68.16元，成交额达7180.52万元，换手率为0.91%。近日，康希诺生物股份公司召开2025年第二次临时股东大会，审议通过了关于取消监事会、修订《公司章程》及其附件并办理工商变更登记的议案，修订部分公司治理制度的议案，以及使用公积金弥补亏损的议案。公告显示，本次会议表决程序合法有效，所有议案均获通过，无被否决议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700038439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2586250392","title":"康希诺：关于回购A股股份注销实施的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250392","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586250392?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:39","pubTimestamp":1764164394,"startTime":"0","endTime":"0","summary":"证券日报网讯11月26日晚间，康希诺发布公告称，本次回购股份注销日期为2025年11月27日，股份注销数量为406，098股A股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263575664492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399300","159982","688185","BK0239"],"gpt_icon":0},{"id":"2583659452","title":"每周股票复盘：康希诺（688185）吸入用肺结核疫苗印尼启动I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659452","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659452?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:36","pubTimestamp":1763231775,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，康希诺报收于75.08元，较上周的74.27元上涨1.09%。本周，康希诺11月14日盘中最高价报77.1元。本周关注点公司公告汇总：康希诺吸入用肺结核疫苗在印度尼西亚启动I期临床试验并完成首例受试者入组。公司公告汇总：康希诺召开2025年第二次临时股东大会，审议取消监事会及修订《公司章程》等议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688185"],"gpt_icon":0},{"id":"2583355472","title":"康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2583355472","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583355472?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:32","pubTimestamp":1763022730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺(688185.SH)发布公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体)(简称“吸入用结核病加强疫苗”)近日于印度尼西亚启动I期临床试验，并完成I期临床首例受试者入组。该I期临床试验于印度尼西亚开展，目的是在18-49岁的成年人中探究接种一剂吸入用肺结核疫苗(5型腺病毒载体)的安全性和免疫原性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK0239","688185"],"gpt_icon":0},{"id":"2582835429","title":"康希诺（688185）披露拟用公积金弥补亏损，11月11日股价下跌0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582835429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582835429?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:26","pubTimestamp":1762853198,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，康希诺报收于75.5元，较前一交易日下跌0.26%，最新总市值为186.82亿元。该股当日开盘75.81元，最高76.87元，最低74.71元，成交额达1.24亿元，换手率为1.43%。近日，康希诺生物股份公司发布2025年第二次临时股东大会会议资料，其中包含多项议案。公告显示，公司拟使用盈余公积和资本公积合计1,450,342,128.90元弥补母公司累计亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100028266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2582861034","title":"每周股票复盘：康希诺（688185）拟用公积金14.5亿元弥补亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861034?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:30","pubTimestamp":1762633830,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，康希诺报收于74.27元，较上周的79.16元下跌6.18%。本周，康希诺11月3日盘中最高价报79.82元。本周关注点公司公告汇总：康希诺拟使用公积金合计1,450,342,128.90元弥补母公司累计亏损。公司公告汇总：康希诺将于2025年11月17日召开第三季度业绩说明会。关于使用公积金弥补亏损的公告康希诺生物股份公司拟使用公积金弥补母公司累计亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2581070024","title":"康希诺（688185）披露拟使用公积金弥补亏损，11月07日股价下跌0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581070024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581070024?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:13","pubTimestamp":1762506820,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，康希诺报收于74.27元，较前一交易日下跌0.26%，最新总市值为183.78亿元。该股当日开盘74.62元，最高74.88元，最低73.6元，成交额达9832.5万元，换手率为1.15%。近日，康希诺生物股份公司发布公告称，拟使用公积金弥补母公司累计亏损。该方案已获董事会、监事会审议通过，尚需股东大会审议。本次弥补亏损有助于提升投资者回报能力，推动公司高质量发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700027053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"gpt_icon":0},{"id":"2578070647","title":"康希诺（688185）披露2025年A股限制性股票激励计划首次授予结果，10月27日股价上涨0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578070647","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578070647?lang=zh_cn&edition=full","pubTime":"2025-10-27 22:18","pubTimestamp":1761574734,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘，康希诺报收于74.61元，较前一交易日上涨0.08%，最新总市值为184.62亿元。近日，康希诺生物股份公司监事会发布关于2025年A股限制性股票激励计划首次授予激励对象名单的核查意见。激励对象符合相关法律法规及《2025年A股限制性股票激励计划（草案）》规定的资格条件和范围，主体资格合法有效，获授条件已成就。监事会同意以2025年10月27日为首次授予日，以41.20元/股的价格向86名激励对象授予2,054,600股限制性股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700036305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","399300","BK0239","688185"],"gpt_icon":0},{"id":"2578957504","title":"每周股票复盘：康希诺（688185）拟注销406098股并推股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2578957504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578957504?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:24","pubTimestamp":1761416652,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，康希诺报收于74.55元，较上周的72.7元上涨2.54%。本周关注点公司公告汇总：康希诺拟注销回购的406,098股A股股份，注册资本将相应减少。公司公告汇总：康希诺审议通过2025年A股限制性股票激励计划及H股购股权计划。康希诺发布关于注销回购A股股份并减少注册资本暨通知债权人的公告，因未在三年期限内将全部回购股份用于员工持股或股权激励，公司拟注销回购专用证券账户中的406,098股A股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767725525782,"stockEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":-0.0092},{"period":"3month","weight":-0.1759},{"period":"6month","weight":0.0734},{"period":"1year","weight":0.1008},{"period":"ytd","weight":0.0426}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.0289}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康希诺生物股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17290人(较上一季度增加0.19%)","perCapita":"6614股","listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","registeredCapital":"24704万元","survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是MCV4、PCV13i、MCV2、Ad5-nCoV、吸入用Ad5-nCoV及XBB.1.5变异株疫苗、Ad5-EBOV。","listedPrice":209.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}